News
02-23-2011, 02:00 AM
Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.
More... (http://www.news-medical.net/news/20110223/Amgen-announces-publication-of-XGEVA-Phase-3-study-results-against-solid-tumors-in-Journal-of-Clinical-Oncology.aspx)
More... (http://www.news-medical.net/news/20110223/Amgen-announces-publication-of-XGEVA-Phase-3-study-results-against-solid-tumors-in-Journal-of-Clinical-Oncology.aspx)